Y
Yi Hsiang Huang
Researcher at Taipei Veterans General Hospital
Publications - 390
Citations - 13443
Yi Hsiang Huang is an academic researcher from Taipei Veterans General Hospital. The author has contributed to research in topics: Hepatocellular carcinoma & Hepatitis B virus. The author has an hindex of 46, co-authored 386 publications receiving 10122 citations. Previous affiliations of Yi Hsiang Huang include National Yang-Ming University & National Taiwan University.
Papers
More filters
Journal ArticleDOI
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix,Shukui Qin,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Marc Pracht,Osamu Yokosuka,Olivier Rosmorduc,Valeriy Breder,René Gerolami,Gianluca Masi,Paul Ross,Tianqiang Song,Jean-Pierre Bronowicki,Isabelle Ollivier-Hourmand,Masatoshi Kudo,Ann-Lii Cheng,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Richard S. Finn,Marie Aude Leberre,Annette Baumhauer,Gerold Meinhardt,Guohong Han +25 more
TL;DR: Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenIB treatment, and future trials should explore combinations of regorAFenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafanib and regorafinib.
Journal ArticleDOI
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister,Dominik Pfister,Nicolás Gonzalo Núñez,Roser Pinyol,Olivier Govaere,Matthias Pinter,Marta Szydlowska,Revant Gupta,Mengjie Qiu,Aleksandra Deczkowska,Assaf Weiner,Florian Müller,Ankit Sinha,Ankit Sinha,Ekaterina Friebel,Thomas Engleitner,Thomas Engleitner,Daniela Lenggenhager,Anja Moncsek,Danijela Heide,Kristin Stirm,Jan Kosla,Eleni Kotsiliti,Valentina Leone,Michael Dudek,Suhail Yousuf,Donato Inverso,Donato Inverso,Indrabahadur Singh,Ana Teijeiro,Florian Castet,Carla Montironi,Philipp K. Haber,Dina Tiniakos,Dina Tiniakos,Pierre Bedossa,Simon Cockell,Ramy Younes,Ramy Younes,Michele Vacca,Fabio Marra,Jörn M. Schattenberg,Michael Allison,Elisabetta Bugianesi,Vlad Ratziu,Tiziana Pressiani,Antonio D'Alessio,Nicola Personeni,Lorenza Rimassa,Ann K. Daly,Bernhard Scheiner,Katharina Pomej,Martha M. Kirstein,Arndt Vogel,Markus Peck-Radosavljevic,F. Hucke,Fabian Finkelmeier,Oliver Waidmann,Jörg Trojan,Kornelius Schulze,Henning Wege,Sandra Koch,Arndt Weinmann,Marco Bueter,Fabian Rössler,Alexander Siebenhüner,Sara De Dosso,Jan-Philipp Mallm,Viktor Umansky,Viktor Umansky,Manfred Jugold,Tom Luedde,Andrea Schietinger,Andrea Schietinger,Peter Schirmacher,Brinda Emu,Hellmut G. Augustin,Hellmut G. Augustin,Adrian T. Billeter,Beat P. Müller-Stich,Hiroto Kikuchi,Dan G. Duda,Fabian Kütting,Dirk Waldschmidt,Matthias P. Ebert,Nuh N. Rahbari,Henrik E. Mei,Axel Schulz,Marc Ringelhan,Nisar P. Malek,Stephan Spahn,Michael Bitzer,Marina Ruiz de Galarreta,Amaia Lujambio,Jean-François Dufour,Thomas U. Marron,Thomas U. Marron,Ahmed Kaseb,Masatoshi Kudo,Yi Hsiang Huang,Yi Hsiang Huang,Nabil Djouder,Katharina Wolter,Lars Zender,Lars Zender,Parice N. Marche,Parice N. Marche,Thomas Decaens,Thomas Decaens,David J. Pinato,Roland Rad,Roland Rad,Joachim C. Mertens,Achim Weber,Kristian Unger,Felix Meissner,Susanne Roth,Zuzana Macek Jilkova,Zuzana Macek Jilkova,Zuzana Macek Jilkova,Manfred Claassen,Quentin M. Anstee,Ido Amit,Percy A. Knolle,Burkhard Becher,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Mathias Heikenwalder +128 more
TL;DR: The progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers provides a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.
Journal ArticleDOI
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma.
Jaw Ching Wu,Jaw Ching Wu,Yi Hsiang Huang,Yi Hsiang Huang,Gar-Yang Chau,Gar-Yang Chau,Chien Wei Su,Chien Wei Su,Chung-Ru Lai,P.-C. Lee,Teh Ia Huo,Teh Ia Huo,I-Jane Sheen,Shou-Dong Lee,Shou-Dong Lee,Wing-Yiu Lui,Wing-Yiu Lui +16 more
TL;DR: Tumor factors wereassociated with early HCC recurrence while high viral loads and hepatic inflammatory activity were associated with late recurrence, and pre- and post-operative antiviral and anti-inflammatory therapies may be crucial in reducing lateRecurrence.
Journal ArticleDOI
Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B
Yi Hsiang Huang,Liang Tsai Hsiao,Ying Chung Hong,Tzeon Jye Chiou,Yuan Bin Yu,Jyh Pyng Gau,Chunyu Liu,Muh Hwa Yang,Cheng Hwai Tzeng,Pui Ching Lee,Han Chieh Lin,Shou-Dong Lee +11 more
TL;DR: Undetectable HBV viral load before chemotherapy did not confer reactivation-free status, but antiviral prophylaxis can potentially prevent rituximab-associated HBV reactivation in patients with lymphoma and resolved hepatitis B.
Journal ArticleDOI
A versatile thermally activated delayed fluorescence emitter for both highly efficient doped and non-doped organic light emitting devices
Wei-Lung Tsai,Ming-Hao Huang,Wei-Kai Lee,Yi-Jiun Hsu,Kuan-Chung Pan,Yi Hsiang Huang,Hao-Chun Ting,Monima Sarma,Yu-Yi Ho,Hu Hung-Chieh,Chung-Chia Chen,Meng-Ting Lee,Ken-Tsung Wong,Chung-Chih Wu +13 more
TL;DR: A thermally activated delayed fluorescent emitter (DMAC-TRZ) was reported either as the emitting dopant in a host or as the non-doped (neat) emitting layer to achieve high EL EQEs of up to 26.5% and 20% in OLEDs, respectively.